BLINATUMOMAB
blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL
vial], 1 pack
BLINATUMOMAB (11850Q)
11850Q
Manner of administration:Injection
Restriction
Indication: Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)
Treatment phase: Initial treatment of newly-diagnosed Pre-B-cell ALL in the consolidation phase
Restriction
Indication: Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)
Treatment phase: Continuing treatment of Pre-B-cell ALL in complete haematological remission (CR)
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 784 mcg | # of repeats: 1 | DPMA: $77,358.07 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Blincyto
(blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL
vial], 1 pack)
|
||||